- Home
- OSTX vs KPTI Comparison
OSTX vs KPTI Comparison
Compare OSTX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- KPTI
- Stock Information
- Founded
- OSTX 2018
- KPTI 2008
- Country
- OSTX United States
- KPTI United States
- Employees
- OSTX N/A
- KPTI N/A
- Industry
- OSTX
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- KPTI Health Care
- Exchange
- OSTX NYSE
- KPTI Nasdaq
- Market Cap
- OSTX 43.0M
- KPTI 44.5M
- IPO Year
- OSTX 2024
- KPTI 2013
- Fundamental
- Price
- OSTX $1.76
- KPTI $4.29
- Analyst Decision
- OSTX Strong Buy
- KPTI Buy
- Analyst Count
- OSTX 3
- KPTI 7
- Target Price
- OSTX $18.00
- KPTI $48.50
- AVG Volume (30 Days)
- OSTX 755.1K
- KPTI 225.9K
- Earning Date
- OSTX 08-14-2025
- KPTI 08-05-2025
- Dividend Yield
- OSTX N/A
- KPTI N/A
- EPS Growth
- OSTX N/A
- KPTI N/A
- EPS
- OSTX N/A
- KPTI N/A
- Revenue
- OSTX N/A
- KPTI $142,126,000.00
- Revenue This Year
- OSTX N/A
- KPTI $2.09
- Revenue Next Year
- OSTX N/A
- KPTI $12.90
- P/E Ratio
- OSTX N/A
- KPTI N/A
- Revenue Growth
- OSTX N/A
- KPTI 1.19
- 52 Week Low
- OSTX $1.12
- KPTI $3.51
- 52 Week High
- OSTX $7.00
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- KPTI 47.74
- Support Level
- OSTX N/A
- KPTI $4.22
- Resistance Level
- OSTX N/A
- KPTI $4.91
- Average True Range (ATR)
- OSTX 0.00
- KPTI 0.45
- MACD
- OSTX 0.00
- KPTI 0.01
- Stochastic Oscillator
- OSTX 0.00
- KPTI 40.28
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.